Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

Is AustralianSuper & PE About To Buy Healthscope Ltd?

Healthscope Ltd (ASX: HSO) has announced that it has received a takeover offer from a consortium led by AustralianSuper and BGH Capital for $2.36 cash per share.

Healthscope Ltd (ASX: HSO) has announced that it has received a takeover offer from a consortium led by AustralianSuper and BGH Capital for $2.36 cash per share. Healthscope is the second largest private hospital operator in Australia.

Healthscope said that it has received an unsolicited proposal from a consortium of investors to buy all of the shares. Those investors are AustralianSuper, BGH Capital Fund, Carob Investment Private Limited (a subsidiary of GIC (Ventures) Private Limited), Ontario Teachers’ Pension Plan Board and Canada Pension Plan Investment Board.

What’s The Price?

The offer of $2.36 represents a premium of 16% compared to the closing share price of $2.03 on Tuesday. However, this would be reduced by the value of any dividends or distributions that are proposed or paid.

According to Healthscope, AustralianSuper already owns around 14% of Healthscope. The entire consortium owns around 14.5% of the shares according to an ASX announcement by the consortium.

However, the Healthscope proposal will have to tick a number of conditions before it could proceed from the purchaser’s side. Some of the conditions include due diligence and arranging debt financing for the acquisition.

More conditions include each consortium member will need to obtain approval to submit a binding proposal from its investment committee, the necessary regulatory approvals will need to be received and the Healthscope Board will need to unanimously recommend that shareholders vote in favour of the proposed scheme unless a better offer appears.

However, AustralianSuper has said it will vote down any other proposal, according to the AFR.

The consortium also doesn’t want Healthscope to sell any of its important assets, including its Asian pathology business.

The Healthscope Board said it has commenced an assessment of the offer and will keep investors informed of any important developments as required. The Board said that shareholders don’t need to do anything at this stage and confirmed that there is no certainty the offer will result in a takeover.

The private hospital operator has appointed investment bank UBS as its financial adviser and Herbert Smith Freehills as its legal adviser.

Did you know it’s free to join The Rask Group’s Investor Club Newsletter? It’s a regular (usually weekly) news and educational update on financial markets, investing and unique strategies. Join today and get ready to laugh and learn.

Click here to join The Rask Group’s Investor Club Newsletter Today

 

Hey, you, read this disclaimer: This article contains information only. It is not financial advice. It is no substitute for trusted and licensed financial advice and should not be relied upon. By using our website you agree to our Code of EthicsDisclaimer & Terms of Use and Privacy Policy. Also, don’t forget, past performance is not a reliable indicator of future performance. 

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

Skip to content